NFW Vascepa[®]: **Power to reduce** the risk of cardiovascular events¹

Vascepa® demonstrated reductions in the risk of CV events vs. placebo (both in combination with statins)1*

2° endpoints **20**[%] (event n=174 vs. 213) CV death^{††} Non-fatal **30**[%] (event n=237 vs. 332) myocardial infarction[†] **129**[°] (event n=85 vs. 118) Non-fatal stroke[†] Vascepa® demonstrated a significant 25% reduction (event n=705 vs. 901) in time to first occurrence of cardiovascular death, MI, stroke, coronary revascularization or hospitalization for unstable angina (5-point MACE) vs. placebo (1° endpoint).1* 95% CI (0.68, 0.83) There was no statistically significant difference in risk between the Vascepa® and placebo groups for all-cause mortality.

A placebo-controlled trial with a 4.9-year median follow-up of statin-treated adult patients with elevated triglycerides and a high risk of cardiovasular events due to established cardiovascular disease or diabetes with at least 1 other CV risk factor.^{1*}

Consider Vascepa®: The first and ONLY icosapent ethyl (IPE) prescription medication¹⁰

To learn more, visit www.vascepa.ca

Vascepa® (icosapent ethyl) is indicated to reduce the risk of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to:

established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor

Clinical use:

Not indicated for pediatric use.

Use in geriatrics is not associated with differences in safety or effectiveness, but greater sensitivity of some older individuals cannot be ruled out.

Relevant warnings and precautions:

• Not recommended in combination with or substituted for other products that contain omega-3 fatty acids

- Increased incidence of bleeding
- Caution in patients with known hypersensitivity to fish and/or shellfish
- Periodic monitoring of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in patients with hepatic impairment is recommended during therapy with Vascepa®
- Fertility
- Not recommended in pregnancy and nursing

For more information:

Please consult the Vascepa® Product Monograph at

https://health-products.canada.ca/dpd-bdpp/index-eng.jsp for important information relating to adverse reactions, drug interactions, and dosing/

HLS Therapeutics®

Vascepa® is a registered trademark of the Amarin group of companies. © Copyright 2020 HLS Therapeutics Inc. HLS Therapeutics Inc., Etobicoke, Ontario VAS 20200413 E COM

administration information which have not been discussed in this piece. The Product Monograph is also available by calling HLS Therapeutics Inc. at 1-833-266-3423.

- * 8,179 statin-treated adult patients with elevated serum triglyceride levels (≥1.5 mmol/L to <5.6 mmol/L) who were also at high risk for atherothrombotic events. Patients either had established CVD or were</p> at high risk for CVD and were randomized to either Vascepa® or placebo. Patients with established at high risk for CVD and were randomized to either Vascepa" or placebo. Patients with established cardiovascular disease were at least 45 years of age and had a documented history of coronary artery disease, cerebrovascular or carotid disease, or peripheral artery disease. Patients with other risk factors for cardiovascular lisk actors. Fonit MACE was defined as time to first occurrence of cardiovascular disease were at least 50 years of age and had diabetes and at least one additional major cardiovascular risk factors. Fonit MACE was defined as time to first occurrence of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. Most patients at baseline were taking at least one other cardiovascular medication including anti-hypertensives (95%), anti-platelet agents (79.4%), beta blockers (70.7%), angiotensin-converting enzyme (ACE) inhibitors (51.9%), and angiotensin receptor blockers (ARB) (27.0%), with 77.5% taking either an ACE inhibitor or ARB.
- At baseline, while on stable background lipid-lowering therapy, the median LDL-C was 1.9 mmol/L † Incidence rates of CV events per 100 patient years (Vascepa® vs. placebo): cardiovascular death, 1.0 vs. 1.2; non-fatal myocardial infarction, 1.4 vs. 2.0; non-fatal stroke, 0.5 vs. 0.7.
- CV death includes adjudicated cardiovascular deaths and deaths of undetermined causality.
- Comparative clinical significance has not been established.
 C, confidence interval; CV, cardiovascular; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event.

Reference:

1. HLS Therapeutics Inc. Vascepa® Product Monograph. 2019.



